NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 270)
Posted On: 05/27/2020 3:19:01 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Targets Massive International Markets
Pressure BioScience (OTCQB: PBIO) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries. On April 29, PBIO announced its entrance into a binding letter of intent to acquire Cannaworx Inc. (http://nnw.fm/f4ANi). An article discussing the company reads, “The merged entity, equipped with an extensive intellectual property portfolio utilizing a proprietary pressure platform, nanotechnology and advanced delivery systems, plans to disrupt a number of major world markets. These include the international cosmetics market, projected to reach $758 billion by 2025 (http://nnw.fm/QCv9q); the global agricultural technology and products market, projected at $729 billion by 2023 (http://nnw.fm/4l24C); the global biopharmaceuticals market, expected to reach $389 billion by 2024 (http://nnw.fm/8w4WS); as well as the U.S. hemp-derived CBD market, anticipated to reach $23.7 billion by 2023 (http://nnw.fm/1nJGb). . . . Cannaworx’s diverse portfolio of products and intellectual property was developed by its founders Bobby Ghalili, DMD, and Adrienne Denese, MD, PhD. Ghalili and Denese bring extensive medical expertise and product innovation into the newly combined public company. They have an impressive multiyear track record of developing and selling personal-care and nutrition products.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioScience (OTCQB: PBIO) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries. On April 29, PBIO announced its entrance into a binding letter of intent to acquire Cannaworx Inc. (http://nnw.fm/f4ANi). An article discussing the company reads, “The merged entity, equipped with an extensive intellectual property portfolio utilizing a proprietary pressure platform, nanotechnology and advanced delivery systems, plans to disrupt a number of major world markets. These include the international cosmetics market, projected to reach $758 billion by 2025 (http://nnw.fm/QCv9q); the global agricultural technology and products market, projected at $729 billion by 2023 (http://nnw.fm/4l24C); the global biopharmaceuticals market, expected to reach $389 billion by 2024 (http://nnw.fm/8w4WS); as well as the U.S. hemp-derived CBD market, anticipated to reach $23.7 billion by 2023 (http://nnw.fm/1nJGb). . . . Cannaworx’s diverse portfolio of products and intellectual property was developed by its founders Bobby Ghalili, DMD, and Adrienne Denese, MD, PhD. Ghalili and Denese bring extensive medical expertise and product innovation into the newly combined public company. They have an impressive multiyear track record of developing and selling personal-care and nutrition products.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)